AB2 Bio appoints Michael Soldan CEO

AB2 Bio Ltd, a Swiss advanced clinical-stage biotech company, specialized in developing innovative therapies for the treatment of severe systemic autoinflammatory diseases including rare diseases with high unmet medical needs, announces the appointment of the experienced pharmaceutical executive Michael Soldan, PhD as its Chief Executive Officer.

Dr Soldan joins from global healthcare company Fresenius Kabi, where he was CEO of the Global Biosimilars Business located in Switzerland, responsible for the successful creation, development, launch and commercialization of biosimilars in the U.S., Europe and other parts of the world. He has an extensive background in general management, drug commercialization, business development and regulatory affairs as well as experience of integrating businesses.

Prior to Fresenius Kabi, Dr Soldan was with Merck Group, where he spent two years heading the biosimilars business. He has also held a number of senior regulatory and clinical positions with companies including Boehringer Ingelheim, Biotest, Grünenthal and Aventis Behring. He holds a degree in Pharmacy and a PhD in Pharmacology from Philipps University Marburg, Germany.

“I am very pleased to welcome Michael Soldan to AB2 Bio, where he will bring the benefit of his impressive and wide-ranging career in the pharmaceuticals industry. Dr Soldan’s extensive experience in manufacturing and regulatory affairs is of direct relevance to prepare the next phase of development of AB2 Bio as we continue the pivotal Phase 3 trial of Tadekinig alfa in patients with monogenic, interleukin-18 driven autoinflammatory conditions and progress it towards market,” says Prof. Andrea Pfeifer, AB2 Bio’s Chairwoman.